IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. We are focused on the development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials.

IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds:

  • Two lead anti-cancer therapies targeting IDO and PD-L1 are in clinical development
  • Several compounds finalizing the preclinical phase

IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board. IO Biotech is a privately held company with a solid financial position funded by experienced investors: Lundbeckfonden Emerge, Novo Seeds & Sunstone. 

IO Biotech is located in Copenhagen, Denmark and was founded in December 2014 as a spin-out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic products.